COLOPHON / THE PUBLISHER
About this BPC-157 research bulletin
An independent editorial project that reads the published BPC-157 record and cites it — and is explicit about what it is not.
What Telehealth BPC-157 is
Telehealth BPC-157 is an independent editorial project that publishes summaries of the peer-reviewed research literature on BPC-157, the stable gastric pentadecapeptide. We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The bulletin reads as an agitprop research board on purpose: the BPC-157 literature is a dossier of discrete, citable facts — a sequence, a half-life, an inhibition ratio, a mechanism, a human-data gap — and the cleanest way to present them is one cited plate at a time. Every quantitative claim on the site maps to a numbered source on the references page.
What the name means, and what it does not
The word "telehealth" in this site's name is editorial framing, not a service claim. It marks the lens this publisher takes on the literature — the clinical-context and medicinal-access angle: who studies BPC-157, how compounded access is described in general terms, and where the FDA 503A record currently stands. It does not mean this site offers consultations, evaluations, prescriptions, or treatment, because it does not. There are no "our doctors," no "our pharmacists," and no clinical team here.
We do not name vendors, pharmacies, clinics, or telehealth providers, and we do not provide dosing or administration instructions. When the regulatory landscape is discussed, it is discussed as general information, not medical or legal advice, and not an offer to sell or supply any substance. The point of the bulletin is to make the published record legible and honestly bounded — including its largest limit, which is that human evidence for BPC-157 remains confined to three small pilot studies.
How we handle the evidence
We separate what the literature establishes from what it merely circulates. Preclinical findings are labeled as preclinical. Human pilots are labeled as small and uncontrolled. Popular claims that the published record does not support — weight loss, muscle building, testosterone increase — are flagged as unsupported. Where a source could not be verified, such as the unconfirmed early-2026 reclassification reports, we say so and leave the current FDA-citable status as the stated fact.
The register is sober by design. The agitprop styling carries the data; it does not inflate it. A bold plate and a single accent color make a citation impossible to skim past, which is the opposite of hype.